Sign inJoin waitlistJoin the waitlist

Saar Gill

Scientific Director, University of Pennsylvania Cell Therapy and Transplant Group · University of Pennsylvania Health System

Credentials: · · · ·

History

Cell Therapy and Transplant Program · University of Pennsylvania Health System
Present
Translational Center of Excellence in Genetically Engineered Hematopoietic Stem Cell Transplantation · University of Pennsylvania Health System
Present
Gill Laboratory · DREXEL UNIVERSITY
Present

Hematology and Medical Oncology
University of Pennsylvania Health System
2012–2015
University of Pennsylvania
2011–2012
Stanford University
2008–2011
UNIV OF MELBOURNE, PARKVILLE, VICTORIA
2008–2011
Peter MacCallum Cancer Centre
2005–2007
St Vincent's Hospital Melbourne
2000–2004
University of Melbourne, 2011
UNIV OF MELBOURNE, PARKVILLE, VICTORIA
1995–1999

Research

Human chimeric antigen receptor macrophages for cancer immunotherapy
Nature Biotechnology · 2020 · Last of 26 authors · Corresponding · 1,236 citations
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
Cancer Discovery · 2015 · 1,091 citations
Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma
Cell · 2010 · 943 citations

David Porter
47 papers
Noelle Frey
40 papers
Carl June
36 papers
Alison Loren
30 papers
Elizabeth Hexner
30 papers
Marco Ruella
26 papers · 21 as a resident
Selina Luger
26 papers
Edward Stadtmauer
23 papers
Mary Martin
21 papers
Shannon McCurdy
17 papers
Alexander Perl
16 papers
CF
Craig Freyer
16 papers

Grants

Defining the Determinants of Long Term CAR-T Persistence
National Cancer Institute · R01
Contact PI · $703.1K · University of Pennsylvania
2026–2031
Immunoengineering Durable Control of HIV Replication
National Institute of Allergy and Infectious Diseases · P01
Project lead · $1.5M · University of Pennsylvania
2025–2030
Enhancing Chimeric Antigen Receptor T Cell Therapies for HematologicMalignancies: Beyond CART 19
National Cancer Institute · P01
Project lead · $2.4M · University of Pennsylvania
2017–2028
Amyloid Beta CAR Macrophages: A Cell Engineering Strategy to Clear Pathogenic Proteins
National Institute of Neurological Disorders and Stroke · R01
Contact PI · $2.8M · University of Pennsylvania
2023–2027

Clinical trials

CART123 + Ruxolitinib in Relapsed/Refractory AML
Principal investigator · Active not recruiting · Phase 1
University of Pennsylvania
2025–2045
Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)
Principal investigator · Terminated · Early phase 1
University of Pennsylvania
2016–2019
CD123 Redirected Autologous T Cells for AML
Principal investigator · Terminated · Early phase 1
University of Pennsylvania
2015–2016
A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation
Site PI · Recruiting · Phase 3
TScan Therapeutics, Inc.
2026–2029